Human Her2 / ErbB2 Protein
Human Her2, His Tag (HE2-H5225) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # AAA75493).
Predicted N-terminus: Thr 23
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.2 kDa. The protein migrates as 110-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Human Her2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human Her2, His Tag (Cat. No.
HE2-H5225) at 0.05 μg/mL (100 μL/well) can bind Trastuzumab with a linear range of 0.2-3 ng/mL (QC tested).
Immobilized Herceptin on CM5 Chip via anti-human Fc IgG, can bind Human Her2 Protein (Cat. No. HE2-H5225) with an affinity constant of 0.147nM as determined in SPR assay (Biacore T200) ( Routinely tested).
Immobilized Herceptin on AHC Biosensor, can bind Human Her2 Protein (Cat. No. HE2-H5225) with an affinity constant of 0.93 nM as determined in BLI assay (Fortebio Octet 96) ( Routinely tested).
Afucosylated protein, cell expressing said protein and associated methods Authors: S Chatterjee, et al. Journal: US20180171028A1 2018 Application: ELISA Request for Full-text Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice Authors: Anami Y, et al. Journal: Nat Commun 2018 Application: ELISA Request for Full-text Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation Authors: Zhou Z, et al. Journal: Bioorg Med Chem 2018 Application: Request for Full-text Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation Authors: Wang JH, et al. Journal: Mol Cancer Ther 2018 Application: ELISA Request for Full-text Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies Authors: Nath N, et al. Journal: J Immunol Methods 2017 Application: ELISA Request for Full-text Quantification of circulating cancer biomarkers via sensitive topographic measurements on single binder nanoarrays Authors: Elena Ambrosetti, et al. Journal: ACS Omega 2017 Application: Multiplex detection & SPR & AFM & ELISA Request for Full-text LEAPS vaccine incorporating HER-2/neu epitope elicits protection that prevents and limits tumor growth and spread of breast cancer in a mouse model Authors: Ken S. Rosenthal, et al. Journal: J Immunol Res 2017 Application: ELISA Request for Full-text Charge variant analysis of proposed biosimilar to Trastuzumab Authors: Dakshinamurthy P, et al. Journal: Biologicals 2017 Application: SPR Request for Full-text Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers Authors: S Shukla, et al. Journal: Biomaterials 2016 Application: ELISA Request for Full-text Determination of drug-to-antibody ratio for antibody-drug conjugates purified from serum Authors: Chen J, et al. Journal: Agilent 2016 Application: Request for Full-text Monoclonal antibodies against HER2 epitope and methods of use thereof Authors: Natalya D Bodyak, et al. Journal: US20150366987A1 2015 Application: ELISA Request for Full-text Quantification of antibody production of individual hybridoma cells by Surface Plasmon Resonance imaging Authors: Stojanović I, et al. Journal: Anal Biochem 2015 Application: SPR Request for Full-text Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo Authors: NDong C, et al. Journal: PLoS One 2015 Application: ELISA Request for Full-text Linear epitopes that generate anti-her-2 antibody responses with trastuzuab- (herceptin) like biological activity Authors: Loral E Showalter Journal: Thesis 2014 Application: ELISA Request for Full-text
Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer,communication at the neuromuscular junction andregulation of cell growth and differentiation.
(1) Kanai, Y. et. al., 1995, Biochem. Biophys. Res. Commun.208:1067. (2) Codony-Seeervat, J. et al., 1999, Cancer Res. 59: 1196-1201. (3) Tzahar, E. et al., 1998, Biochim. Biophys. Acta. 1377: 25-37. (4) Kermit, L. et al, 1999, J. Biol. Chem. 274: 5263-5266. (5) Hellyer, N.J. et. al., 2001, J. Biol. Chem. 276:42153. (6) Daly, R.J., 1999, Growth Factors 16:255.
Promotion & Exhibitions
PEGS Boston 2018
WPC Boston 2018
Datasheet & Documentation
+1 800-810-0816 (US)
+86 400-682-2521 (AP)
Questions & Comments
This web search service is supported by Google Inc.